Protocol Ledger

NCT07754461 · Phase III · RECRUITING

A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

Interventional Phase III clinical trial protocol NCT07754461 sponsored by Boehringer Ingelheim in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-08-24 Enrollment: 600 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07754461
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)600 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07754461
Protocol FieldVerified Registry Value
NCT IdentifierNCT07754461
Consolidated Lead SponsorBoehringer Ingelheim
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment600 participants (ESTIMATED)
Registered Start Date2026-08-24
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07754461
Hospital Research SiteLocationSite Profile
Ark Clinical ResearchLong Beach, CAOpen Hospital Dossier ->
Valley Clinical Trials, Inc.Northridge, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI